Erythrocytosis and Polycythemia Secondary to Testosterone Replacement Therapy in the Aging Male

Sexual Medicine Reviews

Volumn 3, Issue 2, 2015, Pages 101-112

  Jones, Steven D ^a   Dukovac, Thomas ^a   Sangkum, Premsant ^a   Yafi, Faysal A ^a   Hellstrom, Wayne J G ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Erythrocytosis; Hematocrit; Late Onset Hypogonadism; Polycythemia; Testosterone; Testosterone Deficiency; Testosterone Replacement Therapy

Indexed keywords

ERYTHROPOIETIN; HEMOGLOBIN; IRON; TESTOSTERONE;

AGING; ANDROGEN THERAPY; ARTICLE; BIOAVAILABILITY; BONE MARROW; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; ERYTHROCYTOSIS; ERYTHROPOIESIS; HEMATOCRIT; HUMAN; HYPOGONADISM; MALE; POLYCYTHEMIA; PRIORITY JOURNAL; STIMULATION; TREATMENT RESPONSE; VENOUS THROMBOEMBOLISM;

EID: 84979846293     PISSN: 20500513     EISSN: 20500521     Source Type: Journal    
DOI: 10.1002/smrj.43     Document Type: Review

References (93)

1. Araujo AB, O'Donnell AB, Brambilla DJ, Simpson WB, Longcope C, Matsumoto AM, McKinlay JB. Prevalence and incidence of androgen deficiency in middle-aged and older men: Estimates from the Massachusetts Male Aging Study. J Clin Endocrinol Metab 2004;89:5920-5926.
2. American Urological Association. AUA position statement on testosterone therapy. AUA website. 2014. Available at: https://www.auanet.org/about/testosterone-therapy.cfm (accessed July 28, 2014).
3. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, Montori VM ; Task Force, Endocrine Society. Testosterone therapy in men with androgen deficiency syndromes: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010;95:2536-2559.
4. Finkle WD, Greenland S, Ridgeway GK, Adams JL, Frasco MA, Cook MB, Fraumeni JF, Hoover RN. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLoS ONE 2014;9:e85805.
5. Muraleedharan V, Marsh H, Kapoor D, Channer KS, Jones TH. Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes. Eur J Endocrinol 2013;169:725-733.
6. Zhao C, Moon du G, Park JK. Effect of testosterone undecanoate on hematological profiles, blood lipid and viscosity and plasma testosterone level in castrated rabbits. Can Urol Assoc J 2013;7:E221-225.
7. Shahidi NT. Androgens and erythropoiesis. N Engl J Med 1973;289:72-80.
8. Tenover JS. Effects of testosterone supplementation in the aging male. J Clin Endocrinol Metab 1992;75:1092-1098.
9. Calof OM, Singh AB, Lee ML, Kenny AM, Urban RJ, Tenover JL, Bhasin S. Adverse events associated with testosterone replacement in middle-aged and older men: A meta-analysis of randomized, placebo-controlled trials. J Gerontol A Biol Sci Med Sci 2005;60:1451-1457.
10. Fernández-Balsells MM, Murad MH, Lane M, Lampropulos JF, Albuquerque F, Mullan RJ, Agrwal N, Elamin MB, Gallegos-Orozco JF, Wang AT, Erwin PJ, Bhasin S, Montori VM. Clinical review 1: Adverse effects of testosterone therapy in adult men: A systematic review and meta-analysis. J Clin Endocrinol Metab 2010;95:2560-2575.
11. Schreijer AJ, Reitsma PH, Cannegieter SC. High hematocrit as a risk factor for venous thrombosis. Cause or innocent bystander? Haematologica 2010;95:182-184.
12. Isidori AM, Giannetta E, Lenzi A. Male hypogonadism. Pituitary 2008;11:171-180.
13. Conway GS. Clinical manifestations of genetic defects affecting gonadotrophins and their receptors. Clin Endocrinol (Oxf) 1996;45:657-663.
14. Basaria S. Male hypogonadism. Lancet 2014;383:1250-1263.
15. Matsumoto AM. Fundamental aspects of hypogonadism in the aging male. Rev Urol 2003;5(Suppl 1):S3-10.
16. Morley JE, Kaiser FE, Perry HM, Patrick P, Morley PM, Stauber PM, Vellas B, Baumgartner RN, Garry PJ. Longitudinal changes in testosterone, luteinizing hormone, and follicle-stimulating hormone in healthy older men. Metabolism 1997;46:410-413.
17. Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR, Baltimore Longitudinal Study of Aging. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 2001;86:724-731.
18. Sartorius G, Spasevska S, Idan A, Turner L, Forbes E, Zamojska A, Allan CA, Ly LP, Conway AJ, MacLachlan RI, Handelsman DJ. Serum testosterone, dihydrotestosterone and estradiol concentrations in older men self-reporting very good health: The healthy man study. Clin Endocrinol (Oxf) 2012;77:755-763.
19. Travison TG, Araujo AB, Kupelian V, O'Donnell AB, McKinlay JB. The relative contributions of aging, health, and lifestyle factors to serum testosterone decline in men. J Clin Endocrinol Metab 2007;92:549-555.
20. Mulligan T, Frick MF, Zuraw QC, Stemhagen A, McWhirter C. Prevalence of hypogonadism in males aged at least 45 years: The HIM study. Int J Clin Pract 2006;60:762-769.
21. Wang C, Nieschlag E, Swerdloff R, Behre HM, Hellstrom WJ, Gooren LJ, Kaufman JM, Legros JJ, Lunefeld B, Morales A, Morley JE, Schulman C, Thompson IM, Weidner W, Wu FC. Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA and ASA recommendations. Eur J Endocrinol 2008;159:507-514.
22. Diver MJ, Imtiaz KE, Ahmad AM, Vora JP, Fraser WD. Diurnal rhythms of serum total, free and bioavailable testosterone and of SHBG in middle-aged men compared with those in young men. Clin Endocrinol (Oxf) 2003;58:710-717.
23. Matsumoto AM. Andropause: Clinical implications of the decline in serum testosterone levels with aging in men. J Gerontol A Biol Sci Med Sci 2002;57:M76-99.
24. Blute M, Hakimian P, Kashanian J, Shteynshluyger A, Lee M, Shabsigh R. Erectile dysfunction and testosterone deficiency. Front Horm Res 2009;37:108-122.
25. Wu FC, Tajar A, Beynon JM, Pye SR, Silman AJ, Finn JD, O'Neill TW, Bartfai G, Casanueva FF, Forti G, Giwercman A, Han TS, Kula K, Lean ME, Pendleton N, Punab M, Boonen S, Vanderschueren D, Labrie F, Huhtaniemi IT. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med 2010;363:123-135.
26. Barrett-Connor E, Von Mühlen DG, Kritz-Silverstein D. Bioavailable testosterone and depressed mood in older men: The Rancho Bernardo Study. J Clin Endocrinol Metab 1999;84:573-577.
27. Kapoor D, Goodwin E, Channer KS, Jones TH. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol 2006;154:899-906.
28. Katznelson L, Finkelstein JS, Schoenfeld DA, Rosenthal DI, Anderson EJ, Klibanski A. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J Clin Endocrinol Metab 1996;81:4358-4365.
29. Yassin DJ, Doros G, Hammerer PG, Yassin AA. Long-term testosterone treatment in elderly men with hypogonadism and erectile dysfunction reduces obesity parameters and improves metabolic syndrome and health-related quality of life. J Sex Med 2014;11:1567-1576.
30. Nikolaenko L, Jia Y, Wang C, Diaz-Arjonilla M, Yee JK, French SW, Liu PY, Laurel S, Chong C, Lee K, Lue Y, Lee WN, Swerdloff RS. Testosterone replacement ameliorates nonalcoholic fatty liver disease in castrated male rats. Endocrinology 2014;155:417-428.
31. Okada K, Yamaguchi K, Chiba K, Miyake H, Fujisawa M. Comprehensive evaluation of androgen replacement therapy in aging Japanese men with late-onset hypogonadism. Aging Male 2014;17:72-75.
32. Kovac JR, Rajanahally S, Smith RP, Coward RM, Lamb DJ, Lipshultz LI. Patient satisfaction with testosterone replacement therapies: The reasons behind the choices. J Sex Med 2014;11:553-562.
33. Layton JB, Li D, Meier CR, Sharpless JL, Sturmer T, Jick SS, Brookhart MA. Testosterone lab testing and initiation in the United Kingdom and the United States, 2000 to 2011. J Clin Endocrinol Metab 2014;99:835-842.
34. Baillargeon J, Urban RJ, Ottenbacher KJ, Pierson KS, Goodwin JS. Trends in androgen prescribing in the United States, 2001 to 2011. JAMA Intern Med 2013;173:1465-1466.
35. An JJ, Craig Cheetham T, Van Den Eeden S. PS3-36: Testosterone replacement therapy patterns for aging males in a managed care setting. Clin Med Res 2013;11:141.
36. Basaria S, Dobs AS. New modalities of transdermal testosterone replacement. Treat Endocrinol 2003;2:1-9.
37. Lakshman KM, Basaria S. Safety and efficacy of testosterone gel in the treatment of male hypogonadism. Clin Interv Aging 2009;4:397-412.
38. Conaglen HM, Paul RG, Yarndley T, Kamp J, Elston MS, Conaglen JV. Retrospective investigation of testosterone undecanoate depot for the long-term treatment of male hypogonadism in clinical practice. J Sex Med 2014;11:574-582.
39. Jockenhövel F, Vogel E, Reinhardt W, Reinwein D. Effects of various modes of androgen substitution therapy on erythropoiesis. Eur J Med Res 1997;2:293-298.
40. Wittert GA, Chapman IM, Haren MT, Mackintosh S, Coates P, Morley JE. Oral testosterone supplementation increases muscle and decreases fat mass in healthy elderly males with low-normal gonadal status. J Gerontol A Biol Sci Med Sci 2003;58:618-625.
41. Maggio M, Snyder PJ, Ceda GP, Milaneschi Y, Luci M, Cattabiani C, Masoni S, Vignali A, Volpi R, Lauretani F, Peachey H, Valenti G, Cappola AR, Longo D, Ferrucci L. Is the haematopoietic effect of testosterone mediated by erythropoietin? The results of a clinical trial in older men. Andrology 2013;1:24-28.
42. Dean JD, Carnegie C, Rodzvilla J, Smith T. Long-term effects of Testim® 1% testosterone gel in hypogonadal men. Rev Urol 2005;7:87-94.
43. Cavender RK, Fairwall M. Subcutaneous testosterone pellet implant (Testopel®) therapy for men with testosterone deficiency syndrome: A single-site retrospective safety analysis. J Sex Med 2009;6:3177-3192.
44. Wang C, Swerdloff R, Kipnes M, Matsumoto AM, Dobs AS, Cunningham G, Katznelson L, Weber TJ, Friedman TC, Snyder P, Levine HL. New testosterone buccal system (Striant) delivers physiological testosterone levels: Pharmacokinetics study in hypogonadal men. J Clin Endocrinol Metab 2004;89:3821-3829.
45. Bassil N, Alkaade S, Morley JE. The benefits and risks of testosterone replacement therapy: A review. Ther Clin Risk Manag 2009;5:427-448.
46. Francomano D, Ilacqua A, Bruzziches R, Lenzi A, Aversa A. Effects of 5-year treatment with testosterone undecanoate on lower urinary tract symptoms in obese men with hypogonadism and metabolic syndrome. Urology 2014;83:167-173.
47. Cui Y, Zong H, Yan H, Zhang Y. The effect of testosterone replacement therapy on prostate cancer: A systematic review and meta-analysis. Prostate Cancer Prostatic Dis 2014;17:132-143.
48. Kaplan AL, Trinh QD, Sun M, Carter SC, Nguyen PL, Shih YC, Marks LS, Hu JC. Testosterone replacement therapy following the diagnosis of prostate cancer: Outcomes and utilization trends. J Sex Med 2014;11:1063-1070.
49. Kava BR. To treat or not to treat with testosterone replacement therapy: A contemporary review of management of late-onset hypogonadism and critical issues related to prostate cancer. Curr Urol Rep 2014;15:422.
50. Roddam AW, Allen NE, Appleby P, Key TJ, Group EHaPCC. Endogenous sex hormones and prostate cancer: A collaborative analysis of 18 prospective studies. J Natl Cancer Inst 2008;100:170-183.
51. Keohane C, McMullin MF, Harrison C. The diagnosis and management of erythrocytosis. BMJ 2013;347:f6667.
52. Golde DW, Hocking WG, Koeffler HP, Adamson JW. Polycythemia: Mechanisms and management. Ann Intern Med 1981;95:71-87.
53. Kennedy BJ. Stimulation of erythropoiesis by androgenic hormones. Ann Intern Med 1962;57:917-936.
54. Shahidi NT, Diamond LK. Testosterone-induced remission in aplastic anemia of both acquired and congenital types. Further observations in 24 cases. N Engl J Med 1961;264:953-967.
55. Ellegala DB, Alden TD, Couture DE, Vance ML, Maartens NF, Laws ER. Anemia, testosterone, and pituitary adenoma in men. J Neurosurg 2003;98:974-977.
56. Palacios A, Campfield LA, McClure RD, Steiner B, Swerdloff RS. Effect of testosterone enanthate on hematopoiesis in normal men. Fertil Steril 1983;40:100-104.
57. Coviello AD, Kaplan B, Lakshman KM, Chen T, Singh AB, Bhasin S. Effects of graded doses of testosterone on erythropoiesis in healthy young and older men. J Clin Endocrinol Metab 2008;93:914-919.
58. Delev DP, Davcheva DP, Kostadinov ID, Kostadinova II. Effect of testosterone propionate on erythropoiesis after experimental orchiectomy. Folia Med (Plovdiv) 2013;55:51-57.
59. Ip FF, di Pierro I, Brown R, Cunningham I, Handelsman DJ, Liu PY. Trough serum testosterone predicts the development of polycythemia in hypogonadal men treated for up to 21 years with subcutaneous testosterone pellets. Eur J Endocrinol 2010;162:385-390.
60. Swerdloff RS, Wang C. Three-year follow-up of androgen treatment in hypogonadal men: Preliminary report with testosterone gel. Aging Male 2003;6:207-211.
61. Wang C, Cunningham G, Dobs A, Iranmanesh A, Matsumoto AM, Snyder PJ, Weber T, Berman N, Hull L, Swerdloff RS. Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab 2004;89:2085-2098.
62. Bachman E, Travison TG, Basaria S, Davda MN, Guo W, Li M, Westfall JC, Bae H, Gordeuk V, Bhasin S. Testosterone induces erythrocytosis via increased erythropoietin and suppressed hepcidin: Evidence for a new erythropoietin/hemoglobin set point. J Gerontol A Biol Sci Med Sci 2014;69:725-735.
63. Siddique H, Smith JC, Corrall RJ. Reversal of polycythaemia induced by intramuscular androgen replacement using transdermal testosterone therapy. Clin Endocrinol (Oxf) 2004;60:143-145.
64. Fleming MD. The regulation of hepcidin and its effects on systemic and cellular iron metabolism. Hematology Am Soc Hematol Educ Program 2008;2008:151-158.
65. Byron JW. Comparison of the action of 3 H-thymidine and hydroxyurea on testosterone-treated hemopoietic stem cells. Blood 1972;40:198-203.
66. Calado RT, Yewdell WT, Wilkerson KL, Regal JA, Kajigaya S, Stratakis CA, Young NS. Sex hormones, acting on the TERT gene, increase telomerase activity in human primary hematopoietic cells. Blood 2009;114:2236-2243.
67. Haneline LS. TERTrific hormones promote hematopoiesis. Blood 2009;114:2207-2208.
68. Dobs AS, Meikle AW, Arver S, Sanders SW, Caramelli KE, Mazer NA. Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men. J Clin Endocrinol Metab 1999;84:3469-3478.
69. Rhoden EL, Morgentaler A. Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med 2004;350:482-492.
70. Vorkas CK, Vaamonde CM, Glesby MJ. Testosterone replacement therapy and polycythemia in HIV-infected patients. AIDS 2012;26:243-245.
71. Jick SS, Hagberg KW. The risk of adverse outcomes in association with use of testosterone products: A cohort study using the UK-based general practice research database. Br J Clin Pharmacol 2013;75:260-270.
72. Edelstein D, Sivanandy M, Shahani S, Basaria S. The latest options and future agents for treating male hypogonadism. Expert Opin Pharmacother 2007;8:2991-3008.
73. Braekkan SK, Mathiesen EB, Njølstad I, Wilsgaard T, Hansen JB. Hematocrit and risk of venous thromboembolism in a general population. The Tromso study. Haematologica 2010;95:270-275.
74. Vaya A, Suescun M. Hemorheological parameters as independent predictors of venous thromboembolism. Clin Hemorheol Microcirc 2013;53:131-141.
75. Pearson TC, Wetherley-Mein G. Vascular occlusive episodes and venous haematocrit in primary proliferative polycythaemia. Lancet 1978;2:1219-1222.
76. Horne MK, Cullinane AM, Merryman PK, Hoddeson EK. The effect of red blood cells on thrombin generation. Br J Haematol 2006;133:403-408.
77. Vaya A, Falco C, Simo M, Ferrando F, Mira Y, Todoli J, Espana F, Corella D. Influence of lipids and obesity on haemorheological parameters in patients with deep vein thrombosis. Thromb Haemost 2007;98:621-626.
78. Eischer L, Tscholl V, Heinze G, Traby L, Kyrle PA, Eichinger S. Hematocrit and the risk of recurrent venous thrombosis: A prospective cohort study. PLoS ONE 2012;7:e38705.
79. Greenberg G, Assali A, Vaknin-Assa H, Brosh D, Teplitsky I, Fuchs S, Battler A, Kornowski R, Lev EI. Hematocrit level as a marker of outcome in ST-segment elevation myocardial infarction. Am J Cardiol 2010;105:435-440.
80. Paul L, Jeemon P, Hewitt J, McCallum L, Higgins P, Walters M, McClure J, Dawson J, Meredith P, Jones GC, Muir S, Dominiczak AF, Lowe G, McInnes GT, Padmanabhan S. Hematocrit predicts long-term mortality in a nonlinear and sex-specific manner in hypertensive adults. Hypertension 2012;60:631-638.
81. Jin YZ, Zheng DH, Duan ZY, Lin YZ, Zhang XY, Wang JR, Han S, Wang GF, Zhang YJ. Relationship between hematocrit level and cardiovascular risk factors in a community-based population. J Clin Lab Anal 2015. DOI: 10.1002/jcla.21767.
82. Krauss DJ, Taub HA, Lantinga LJ, Dunsky MH, Kelly CM. Risks of blood volume changes in hypogonadal men treated with testosterone enanthate for erectile impotence. J Urol 1991;146:1566-1570.
83. Fazio G, Caracciolo C, Barone R, D'angelo L, Di Maggio R, Vernuccio F, Siragusa S. An unknown cause of aortic valve stenosis: Polycythemia vera. J Thromb Thrombolysis 2013;35:282-285.
84. Liu M, Shinkai K. Reversible aquagenic pruritus associated with testosterone-induced erythrocytosis. J Am Acad Dermatol 2014;70:e139-140.
85. Tsai AW, Cushman M, Rosamond WD, Heckbert SR, Polak JF, Folsom AR. Cardiovascular risk factors and venous thromboembolism incidence: The longitudinal investigation of thromboembolism etiology. Arch Intern Med 2002;162:1182-1189.
86. Shibata J, Hasegawa J, Siemens HJ, Wolber E, Dibbelt L, Li D, Katschinski DM, Fandrey J, Jelkmann W, Gassmann M, Wenger RH, Wagner KF. Hemostasis and coagulation at a hematocrit level of 0.85: Functional consequences of erythrocytosis. Blood 2003;101:4416-4422.
87. Tangredi JF, Buxton IL. Hypertension as a complication of topical testosterone therapy. Ann Pharmacother 2001;35:1205-1207.
88. Corona G, Maseroli E, Rastrelli G, Isidori AM, Sforza A, Mannucci E, Maggi M. Cardiovascular risk associated with testosterone-boosting medications: A systematic review and meta-analysis. Expert Opin Drug Saf 2014;13:1327-1351.
89. Distelmaier K, Maurer G, Goliasch G. Blood count in new onset atrial fibrillation after acute myocardial infarction-A hypothesis generating study. Indian J Med Res 2014;139:579-584.
90. Holsworth RE, Cho YI, Weidman JJ, Sloop GD, St Cyr JA. Cardiovascular benefits of phlebotomy: Relationship to changes in hemorheological variables. Perfusion 2014;29:102-116.
91. Guay AT, Jacobson J, Perez JB, Hodge MB, Velasquez E. Clomiphene increases free testosterone levels in men with both secondary hypogonadism and erectile dysfunction: Who does and does not benefit? Int J Impot Res 2003;15:156-165.
92. Kaminetsky J, Hemani ML. Clomiphene citrate and enclomiphene for the treatment of hypogonadal androgen deficiency. Expert Opin Investig Drugs 2009;18:1947-1955.
93. Yarrow JF, Conover CF, McCoy SC, Lipinska JA, Santillana CA, Hance JM, Cannady DF, VanPelt TD, Sanchez J, Conrad BP, Pingel JE, Wronski TJ, Borst SE. 17β-Hydroxyestra-4, 9, 11-trien-3-one (trenbolone) exhibits tissue selective anabolic activity: Effects on muscle, bone, adiposity, hemoglobin, and prostate. Am J Physiol Endocrinol Metab 2011;300:E650-660.